Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid tumors.
In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.Picoplatin Clinical Results, Poniard Pharmaceuticals However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer.Poniard shares crash on Phase III picoplatin failure, fiercebiotech.com, November 16, 2009 Hopes are now pinned on its use for metastatic colorectal cancer.http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009
References